ArticleTheScientificWorldJournal2013
Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease.
Article in TheScientificWorldJournal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.Drug design, development and therapy · 2017Trial
- Trial
- RAGE/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the "Inside - Out".Atherosclerosis · 2024Review
- A Role for Advanced Glycation End Products in Molecular Ageing.International journal of molecular sciences · 2023Review
- Impact of microvascular complications on the outcomes of diabetic foot in type 2 diabetic patients with documented peripheral artery disease.Endocrine · 2023Article
- AGE-RAGE Stress and Coronary Artery Disease.The International journal of angiology : official publication of the International College of Angiology, Inc · 2021Review
- Article
- AGE-RAGE Axis in the Pathophysiology of Chronic Lower Limb Ischemia and a Novel Strategy for Its Treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2020Review
- Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects.Oxidative medicine and cellular longevity · 2020Review
- Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models.Frontiers in cardiovascular medicine · 2020Review
- sRAGE and early signs of cardiac target organ damage in mild hypertensives.Cardiovascular diabetology · 2019Article
- Article
- Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease.Chronic respiratory disease · 2016Article
- Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.Reproductive sciences (Thousand Oaks, Calif.) · 2015Review
- Dietary advanced glycation end products and their role in health and disease.Advances in nutrition (Bethesda, Md.) · 2015Review
- Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome.BioMed research international · 2015Review
- The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes.Respiratory research · 2014Article
- Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- The role of novel atherosclerosis markers in peripheral artery disease: is there a gender difference?Cardiovascular journal of AfricaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study was define in a relatively large patient population with coronary artery disease (CAD) whether the concomitant presence of peripheral artery disease (PAD), which is known to convey additional cardiovascular risk, was associated with different circulating levels of sRAGE with respect to CAD alone and control subjects. Clinical and laboratory parameters including the ankle brachial index (ABI) and sRAGE (enzyme-linked immunosorbent assay kit) were investigated in 544 patients with angiographically documented CAD and 328 control subjects. 213/554 CAD patients (39%) showed an ABI <0.9 associated with typical symptoms (group CAD + PAD), whereas 331 patients were free from PAD. The concentration of plasma sRAGE was significantly lower (P < 0.0001) in CAD population, with and without PAD, than in control subjects. Among CAD patients, those with PAD showed lower levels of sRAGE. The distribution of the three groups (CAD, CAD + PAD, and controls) according to sRAGE tertiles showed that lower levels were more frequent in patients with CAD and CAD + PAD, whereas higher levels were more frequently found in controls. CAD patients presenting with PAD have lower sRAGE levels than CAD patients without peripheral atherosclerosis showing that stable atherosclerotic lesions in different vascular districts are inversely related to soluble decoy receptor sRAGE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.